Rep. Robert Bresnahan, Jr. Sells Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Zimmer Biomet Holdings, Inc. NYSE: ZBH. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in Zimmer Biomet stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Texas Instruments NASDAQ: TXN on 5/15/2025.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $0.55 during mid-day trading on Friday, reaching $92.47. The company had a trading volume of 1,003,196 shares, compared to its average volume of 1,801,629. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $18.30 billion, a P/E ratio of 20.78, a P/E/G ratio of 1.95 and a beta of 0.78. The business has a fifty day simple moving average of $98.35 and a 200 day simple moving average of $104.26.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.94 earnings per share. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio is 21.24%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ZBH. Raymond James lowered their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Robert W. Baird decreased their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, JMP Securities decreased their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $111.53.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $204,000. Kingswood Wealth Advisors LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $229,000. Blue Trust Inc. increased its holdings in shares of Zimmer Biomet by 18.3% in the 4th quarter. Blue Trust Inc. now owns 2,033 shares of the medical equipment provider's stock worth $219,000 after buying an additional 314 shares during the last quarter. KBC Group NV increased its holdings in shares of Zimmer Biomet by 15.7% in the 4th quarter. KBC Group NV now owns 29,264 shares of the medical equipment provider's stock worth $3,092,000 after buying an additional 3,977 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Zimmer Biomet in the 4th quarter worth $63,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.